Literature DB >> 22861669

A pathway to improved prospective observational post-authorization safety studies.

Victor A Kiri1.   

Abstract

Randomized controlled trials (RCTs) are the gold standard for assessing the efficacy of drugs but not necessarily so for drug safety where inadequate power to detect either multiple or rare adverse events is a major handicap. Furthermore, the conditions under which drugs are approved for market use are often different from the settings in actual use. Indeed, with their control mechanisms, trials are by design largely inadequate for the identification of potential safety signals, especially of the rare type, hence the value of postmarketing surveillance and risk management plan-based activities. Today, clinical trials constitute only a part of the research that goes into assessing the safety of drugs. Observational studies, where the investigators merely collect data on treatments received by patients and their health status in routine clinical practice are increasing in uptake because they reflect the real-life utility of drugs, despite the absence of random treatment assignment. Although such studies generally provide less compelling evidence than RCTs, they can be far more useful to drug safety assessment activities than generally acknowledged. An increasing number of post-authorization safety studies (PASS) within the European Medicines Agency's jurisdiction are of the observational type - considered perhaps as more appropriate vehicles for exploring and documenting how products perform in the real world. A similar trend is emerging in the US following the FDA Amendments Act of 2007; since early 2010, an increasing number of post-approval commitments mandated by the FDA include observational studies. However, despite this pattern, not much is known about ongoing efforts to address many of the recognized inadequacies associated with existing methodologies and practices currently adopted in observational PASS. This current opinion presents an overview of some of the main challenges we face in prospective observational PASS, mainly from practical experience, and proposes certain steps for improvement.

Entities:  

Mesh:

Year:  2012        PMID: 22861669     DOI: 10.1007/bf03261968

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  79 in total

1.  Comparing longitudinal binary outcomes in an observational oral health study.

Authors:  Brent J Shelton; Gregg H Gilbert; Zhenmei Lu; Patrick Bradshaw; L Scott Chavers; George Howard
Journal:  Stat Med       Date:  2003-06-30       Impact factor: 2.373

2.  What is the best evidence for determining harms of medical treatment?

Authors:  Jan P Vandenbroucke
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

3.  Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.

Authors:  Panagiotis N Papanikolaou; Georgia D Christidi; John P A Ioannidis
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

4.  How real is intention-to-treat (ITT) analysis in non-interventional post authorization safety studies? We can do better.

Authors:  Victor A Kiri; Gilbert MacKenzie
Journal:  Curr Drug Saf       Date:  2009-05

5.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

6.  The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization.

Authors:  W H Crown; R L Obenchain; L Englehart; T Lair; D P Buesching; T Croghan
Journal:  Stat Med       Date:  1998-09-15       Impact factor: 2.373

7.  Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Authors:  Stephen P Motsko; Karen L Rascati; Anthony J Busti; James P Wilson; Jamie C Barner; Kenneth A Lawson; Jason Worchel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions.

Authors:  O S Miettinen; J J Caro
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

9.  The risk of venous thromboembolism in users of postcoital contraceptive pills.

Authors:  C Vasilakis; S S Jick; H Jick
Journal:  Contraception       Date:  1999-02       Impact factor: 3.375

10.  Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Sabine M J M Straus; Toine C G Egberts; Stella Blackburn; Ingemar Persson; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more
  4 in total

1.  Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.

Authors:  Rolina D van Gaalen; Michal Abrahamowicz; David L Buckeridge
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  Infants fed formula with added long chain polyunsaturated fatty acids have reduced incidence of respiratory illnesses and diarrhea during the first year of life.

Authors:  Alexandre Lapillonne; Nitida Pastor; Weihong Zhuang; Deolinda M F Scalabrin
Journal:  BMC Pediatr       Date:  2014-07-02       Impact factor: 2.125

3.  Data Collection in Multiple Sclerosis: The MSDS Approach.

Authors:  Tjalf Ziemssen; Raimar Kern; Isabel Voigt; Rocco Haase
Journal:  Front Neurol       Date:  2020-06-16       Impact factor: 4.003

Review 4.  Navigating the maze of requirements for obtaining approval of non-interventional studies (NIS) in the European Union.

Authors:  Isabelle Ramirez
Journal:  Ger Med Sci       Date:  2015-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.